Women with peripartum cardiomyopathy (PPCM) presenting as heart failure with reduced ejection fraction (HFrEF) in the last month of pregnancy or in the months following delivery
Guideline-directed pharmacological therapy for HFrEF (respecting contraindications during pregnancy/lactation) and bromocriptine
This updated position statement provides comprehensive guidance on the diagnosis and management of peripartum cardiomyopathy, emphasizing early detection, standard HFrEF therapy, and the potential role of bromocriptine.
Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition typically presenting as heart failure with reduced ejection fraction (HFrEF) in the last month of pregnancy or in the months following delivery in women without another known cause of heart failure. This updated position statement summarizes the knowledge about pathophysiological mechanisms, risk factors, clinical presentation, diagnosis and management of PPCM. As shortness of breath, fatigue and leg oedema are common in the peripartum period, a high index of suspicion is required to not miss the diagnosis. Measurement of natriuretic peptides, electrocardiography and echocardiography are recommended to promptly diagnose or exclude heart failure/PPCM. Important differential diagnoses include pulmonary embolism, myocardial infarction, hypertensive heart disease during pregnancy, and pre-existing heart disease. A genetic contribution is present in up to 20% of PPCM, in particular titin truncating variant. PPCM is associated with high morbidity and mortality, but also with a high probability of partial and often full recovery. Use of guideline-directed pharmacological therapy for HFrEF is recommended in all patients respecting contraindications during pregnancy/lactation. The oxidative stress-mediated cleavage of the hormone prolactin into a cardiotoxic fragment has been identified as a driver of PPCM pathophysiology. Pharmacological blockade of prolactin release using bromocriptine as a disease-specific therapy in addition to standard therapy for heart failure treatment has shown promising results in two clinical trials. Thresholds for devices (implantable cardioverter-defibrillators, cardiac resynchronization therapy and implanted long-term ventricular assist devices) are higher in PPCM than in other conditions because of the high rate of recovery. The important role of education and counselling around contraception and future pregnancies is emphasised.
Building similarity graph...
Analyzing shared references across papers
Loading...
Johann Bauersachs
Heart Failure & Transplant
Tobias König
Medizinische Hochschule Hannover
Peter van der Meer
Heart Failure & Transplant
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
European Journal of Heart Failure
Imperial College London
Université Paris Cité
Karolinska Institutet
Building similarity graph...
Analyzing shared references across papers
Loading...
Bauersachs et al. (Thu,) studied this question.
synapsesocial.com/papers/69d762dfaa68b335b4f312b4 — DOI: https://doi.org/10.1002/ejhf.1493
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: